Canopy Growth's Medical Marijuana Sales Are Soaring. Is the Beaten-Down Stock Ready to Rebound?

Canopy Growth’s fiscal 2026 results were mixed: medical marijuana revenue rose 17% for the full year and 27% in Q4, but recreational cannabis grew only 1% in Q4, international cannabis sales fell 7% year over year, and Storz & Bickel sales declined 14% for both the quarter and full year. Gross margin compressed by 4 percentage points in Q4 and 6 points for the year, and the company posted another year of negative earnings after recapitalizing its balance sheet through a debt-for-equity exchange. The article argues the stock remains a speculative turnaround given only one clearly strong division.

Analysis

The key read-through is not just that CGC is weak; it is that the company is converging toward a single-engine model where one segment is doing the work of the entire equity story while the rest of the portfolio drags on margins and capital allocation. That creates a classic quality trap: top-line stability can mask deteriorating unit economics, especially when gross margin is already compressing and the balance sheet has been restructured rather than organically repaired. In that setup, any incremental revenue growth from the strongest division is likely to be absorbed by mix pressure, integration costs, and ongoing restructuring leakage rather than translating into durable equity value.

The second-order effect is competitive, not just company-specific. If medical remains the only consistently functioning channel, capital and management attention will be pulled further away from recreational, international, and hardware segments, which likely accelerates share loss in the weaker categories versus better-capitalized peers. The hardware decline is especially important because it implies the ecosystem strategy is failing to create recurring attach; that reduces pricing power and weakens the moat around the profitable medical franchise. In cannabis, where distribution and shelf-space relationships are fragile, underinvestment can become self-reinforcing within 2-3 quarters.

For timing, the stock can still bounce in the near term because heavily shorted, low-float names often react to any evidence of category growth or restructuring headlines. But over a 6-12 month horizon, the setup remains unfavorable unless margin trends inflect first, not just revenue. The market will eventually force a choice between pursuing growth and preserving cash; if capital markets close, dilution risk rises again, which caps upside even if sentiment improves temporarily.

Key Decisions for Investors

• Avoid long exposure to CGC for now; the risk/reward is skewed by margin compression and recurring financing overhang. Use any post-earnings pop to fade rallies over a 2-6 week horizon, with a stop above the prior squeeze high.
• If expressing a relative view, pair long stronger, better-capitalized cannabis operators against CGC over the next 1-3 months; the thesis is that capital will continue to rotate toward names with cleaner margin trajectories and less dilution risk.
• Consider a small, tactical short-dated put structure on CGC only if borrow is manageable and implied vol is not already extreme. This is a trade on delayed operating leverage and balance-sheet fatigue, not on sector collapse.
• Watch for a 1-2 quarter confirmation window on medical-margin stabilization before revisiting the long case. If gross margin stops falling and the weaker segments are reined in, the stock could re-rate sharply off a depressed base.
• Do not extrapolate the M&A headline into a durable moat story yet; any long thesis needs evidence that integration is accretive within 6 months, otherwise the acquisition is more likely to be a temporary support for revenue than a true value creator.